Treatment for Vasculitis

Initial Treatment Approach

The American College of Rheumatology recommends high-dose glucocorticoids (prednisone 40-60 mg daily) plus a non-glucocorticoid immunosuppressive agent as the initial therapy to induce remission and minimize glucocorticoid toxicity in patients with active Takayasu arteritis 1, 2
High-dose glucocorticoids (prednisone 40-60 mg daily) should be started promptly upon diagnosis to control inflammation in patients with Takayasu arteritis, with a strength of evidence rated as high 3, 2
Methotrexate (20-25 mg/week) is often used as the initial non-glucocorticoid agent, especially in children due to better tolerability, with a moderate level of evidence supporting its use 1, 3
Alternative first-line immunosuppressants include azathioprine (2 mg/kg/day) and TNF inhibitors, with a low to moderate level of evidence supporting their use 3, 4

Regular clinical assessment combined with inflammatory markers (ESR, CRP) is recommended to monitor disease activity in patients with Takayasu arteritis, with a high level of evidence supporting its use 3, 5
Scheduled non-invasive imaging (MRI, CT angiography, or FDG-PET) is recommended to detect subclinical disease activity in patients with Takayasu arteritis, with a moderate to high level of evidence supporting its use 5, 4
New vascular lesions on imaging warrant immunosuppressive therapy even if clinically asymptomatic, with a high level of evidence supporting this approach 5

For disease refractory to initial therapy, TNF inhibitors are conditionally recommended over tocilizumab, with a moderate level of evidence supporting their use 1
Tocilizumab may be considered when TNF inhibitors are contraindicated or ineffective, with a low level of evidence supporting its use 4

Surgical intervention should be delayed until disease is quiescent in patients with Takayasu arteritis, with a high level of evidence supporting this approach 6, 3
Medical management is preferred over surgical intervention for renovascular hypertension and renal artery stenosis in patients with Takayasu arteritis, with a moderate to high level of evidence supporting this approach 6

High-dose glucocorticoids combined with cyclophosphamide is the standard treatment for severe polyarteritis nodosa, with antiviral therapy added for HBV-associated cases, as recommended by the European League Against Rheumatism 8
High-dose glucocorticoids (1 mg/kg/day of prednisone) are recommended for initial control of inflammation in patients with polyarteritis nodosa, with a high level of evidence supporting its use 8

Treatment for Behcet disease must be tailored to organ involvement, with colchicine for mucocutaneous manifestations and immunosuppressants for severe organ involvement, as recommended by the European League Against Rheumatism 8
Mucocutaneous lesions can be treated with colchicine, topical steroids, and short courses of oral glucocorticoids, with a moderate level of evidence supporting this approach 8

For uncomplicated HSP with primarily cutaneous and joint manifestations, supportive care is sufficient, while glucocorticoids are indicated for gastrointestinal or renal involvement, as recommended by the American College of Rheumatology 8
Mild disease (skin and joint involvement only) can be managed with supportive care, including adequate hydration and pain management, with a high level of evidence supporting this approach 8
Gastrointestinal involvement requires a short course of glucocorticoids (1-2 mg/kg/day), with a moderate level of evidence supporting its use 8
Renal involvement requires high-dose glucocorticoids, with the addition of cyclophosphamide, azathioprine, or mycophenolate mofetil for severe nephritis, with a moderate to high level of evidence supporting this approach 8